Could chemo plus immunotherapy double the punch against tough lung cancers?
NCT ID NCT07715396
First seen Jul 20, 2026 · Last updated Jul 23, 2026 · Updated 3 times
Summary
This phase 3 trial investigates whether adding platinum-based chemotherapy to the immunotherapy drug tislelizumab helps people with a specific type of advanced lung cancer live longer without the disease worsening. Participants have non-small cell lung cancer that has spread, shows high levels of PD-L1 (a protein that helps cancer hide from the immune system), and includes at least one large tumor. The study compares the combination therapy against tislelizumab alone and also against another immunotherapy, pembrolizumab, to see which approach works best.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tislelizumab, an immunotherapy drug, combined with platinum-based chemotherapy
- What this could lead to
- If successful, this could establish a more effective first-line treatment for people with advanced lung cancer that has high PD-L1 expression and large tumors.
- What could go wrong
- Adding chemotherapy increases side effects, and it is not yet known whether the combination improves survival more than immunotherapy alone in this specific group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER WITH A HIGH TUMOR BURDEN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Frankfurt
Frankfurt, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a lung cancer drug designed for one mutation work for another?
- Should all advanced lung cancer patients get a brain scan? new trial aims to find out
- New hope for tough lung cancer? trial tests targeted drug against chemo
- New combo therapy for lung cancer under Real-World watch
- New combo tackles lung cancer after immunotherapy fails
- New cocktail targets lung cancer in the brain: triple therapy shows promise in early trial